BioSpace News Archive

Chemomab Therapeutics Ltd. announced that CEO Dr. Adi Mor and other members of its senior management team will participate in two upcoming investor conferences.

AnaMar, a clinical-stage biotech company developing first-in-class anti-fibrotic 5-HT2B receptor antagonists, announces that the European Medicines Agency and the United States Food and Drug Administration have granted orphan drug designation to its lead clinical candidate, AM1476 for the treatment of systemic sclerosis.

Elanco Animal Health Incorporated announced it has entered into an agreement to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash, which represents approximately 7.4x the estimated 2023 revenue of the Elanco aqua business.

Sirnaomics Ltd. presented the latest developments on Polypeptide Nanoparticle (PNP) platform, and its pipeline program STP705 for Focal Fat Reduction’s positive clinical data, at IMCAS World Congress 2024, which is taking place in Paris from February 1st - 3rd, 2024.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

FibroGen, Inc. announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET.

Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024, before the open of the U.S. financial markets.

Element Biosciences, Inc., developer of pioneering technologies to empower science, will present details on five new products launching in 2024 at the Advances in Genome Biology and Technology General Meeting Feb. 5-8, 2024, in Orlando, FL.

Bruker Introduces the Ingenious Novel ‘ Triceratops ’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024.

Aurora Spine Corporation today announced the issuance of its second United States Patent No: 11,850,162 entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use” for The World’s First DEXA Technology™ Patient-Matched Implant Technology.